Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Priority Reviews At US FDA: From Third Quarter Spikes To A Third Quarter Trough

Oct 01 2018

• By Michael Cipriano

group of businessman in black suit and holding red arrow down graph

Related Content

Priority Review Designations In US: Third Quarter Spike Continues In 2017

Nov 07 2017

Breakthrough Status Arrives Late In Development Of Yervoy+Opdivo, Enfortumab Vedotin And Pedmark

Mar 30 2018

Breakthrough Therapy Designations Set Quarterly Record

Apr 03 2018

Keeping Track: A Long-Awaited Approval For Generic EpiPen, Cancer Product Labels Expand And Constrict

Aug 19 2018

Keeping Track: An Approval For Ajovy, A CRL For Ruconest, And Some Submissions from J&J

Sep 23 2018

US FDA Sets Records With Breakthrough Therapy, Priority Review Designations In 2017

Jan 08 2018

Breakthrough, Priority Review Designations Could Set High-Water Marks In 2018

Jul 06 2018

Related Companies

Intra-Cellular Therapies, Inc.

Johnson & Johnson

Karyopharm Therapeutics

Pfizer Inc.

Genentech, Inc.

Eisai Co., Ltd.

Merck & Co., Inc.

Daiichi Sankyo Co., Ltd.

Array BioPharma, Inc.

Y-mAbs Therapeutics Inc.

AstraZeneca PLC

Amgen, Inc.

Additional Topics

United States Review Pathway Research & Development Drug Review Regulation BioPharmaceutical

More from Review Pathways

More from Pathways & Standards

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window